AcelRx Pharmaceuticals (NASDAQ: ACRX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference
AcelRx Pharmaceuticals (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. An NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) was recently submitted to the FDA for review. The company's follow on product, ZALVISO® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting, is currently enrolling patients in a phase 3 clinical trial, IAP312. For more information, visit the company's website at www.acelrx.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services…